Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

Bio-Rad (BIO) suffers due to funding issue within BioPharma, macroeconomic headwinds and competitive pressures. The stock carries a Zacks Rank #4 (Sell) at present.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, wherein the demand for life science products has been strong historically. This directly correlates with the funding constraints that the broader pharmaceutical industry has started to experience. Management puts forth that BioPharma’s softness has r ...